Can this treatment help repair damage?

Keep the claim narrow.

FDA is short for Food and Drug Administration; it is the U.S. drug agency.

FDA approval belongs to a specific product and its named uses, as of September 2026.

• What exact result is being claimed?
• Which medicine was studied, and how was it given: as a pill, by injection, or in another form?
• Who took part, and did they have my condition?
• What does the evidence leave unanswered?

What if the plan names BPC-157?

For BPC-157, FDA drug records showed no approved U.S. product in September 2026.

In September 2026, FDA reported little or no safety information from people for the ways BPC-157 was proposed to be given.

That leaves FDA without enough information to judge whether those uses could harm people.

Raw ingredients are the starting materials used to make a medicine.

As of September 2026, BPC-157 did not qualify under the legal rules for an ordinary pharmacy to make it from raw ingredients.

• Ask for studies in people that tested the medicine in the way it is being offered to you.
• Ask what remains unknown.
• Ask what other approaches could address the same problem.

What if an offer cites a committee vote?

As of September 2026, a vote by an FDA committee was advice, not legal permission for a pharmacy to use an ingredient. FDA must publish a rule and invite public comments to change its list of permitted raw ingredients for ordinary pharmacies.

• Ask to see the published rule that allows the pharmacy to use this ingredient.
• Check the date on the official record.
• Ask whether that rule covers the exact medicine being offered to you.

Bring the answer back to your goal.

Write the goal in ordinary words. “Less pain when I walk” is a clearer question than a broad claim about renewal.

• What change would count as progress?
• How would we check for that change?
• When would we revisit the plan if it did not help?